Log In
Print this Print this

Personalized SLP immunotherapy

  Manage Alerts
Collapse Summary General Information
Company ISA Pharmaceuticals B.V.
DescriptionDevelopment and delivery process of a set of synthetic long peptides (SLPs) designed to target mutation derived neo-antigen harboring cancer cells
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat various cancers
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today